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This study sought to answer if Justicia flava leaf extract (JF) could inhibit human myometrial 
contractility as was previously shown in mouse myometrium. The study has clearly shown 
that JF abolished human myometrial contractions and therefore presents as a lead plant in 
drug discovery studies involving drugs for preterm birth. 
Abstract 
In the search for new potent therapies for preterm labour, Justicia flava leaves (JF) were 
previously shown to potently inhibit uterine contractility in both pregnant and non-pregnant 
mouse uterus. This study took the investigation a step further and investigated the activity of 
JF on pregnant human myometrial contractility. JF potently inhibited human myometrial 
contractility in a concentration-dependent manner. This pilot study provides evidence that JF 
should be further investigated as a lead plant in the drug discovery of new uterine relaxants.  
Keywords: Tocolytic; uterus; preterm labour; plant; extract; spontaneous contraction; human 
uterus; Justicia flava; Acanthaceae; myometrium; preterm birth. 
 
 
1.1 Introduction  
Preterm birth (PTB) is a major cause of neonatal and maternal mortality and morbidity (Liu 
et al., 2016; van Vliet, et al., 2014) and is defined as birth or delivery that occurs before 37 
weeks gestation (Frey & Klebanoff, 2016). Spontaneous preterm contractions constitute a 
major cause of PTB. Inhibition of uterine contractility (tocolysis) is therefore considered as 
part of therapeutic efforts to combat PTB (Simões-Wüst et al., 2018). Currently available 
drugs (such as, oxytocin receptor antagonists, β-adrenergic agonists, magnesium sulfate, 
calcium-channel blockers) have demonstrated varying efficacy in randomised controlled 
trials and some have side effects that limit their use (Berkman et al., 2003). This has led to 
the search for new effective tocolytics to combat preterm labour (PTL) and reduce the 
incidence of PTB. Plants are a source of new tocolytic therapies, and the plant Bryophyllum 
pinnatum has successfully made it to clinical trials as a tocolytic agent (Simões-Wüst et al., 
2018). One other such plant of growing interest is Justicia flava. The leaves of J. flava are 
regularly used in the South of Nigeria to prevent miscarriages (Bafor et al., 2019) possibly 
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through myometrial contractility inhibition. For this reason, the plant was selected and 
explored extensively on mouse models for its activity on uterine contractility and the female 
reproductive system (Bafor et al., 2020; Bafor et al., 2019). Based on the success of mouse 
experimentation and the inhibitory activity of J. flava on mouse uterine contractility, it was, 
therefore, necessary to determine the efficacy of the plant on human myometrial contractility.  
 This pilot study, therefore, provides proof of concept that an extract from the leaves of 
J. flava potently inhibits pregnant human myometrial contractility and may be a good 
candidate for further clinical evaluation as a novel tocolytic.  
 
2.1 Materials and Methods 
2.1.1 Ethical Approval 
Non-labouring human myometrial biopsies were obtained from women with full term, 
uncomplicated singleton pregnancies undergoing elective Caesarean section (CS) (median 
gestation 39 weeks, n = 9 at Liverpool Women's Hospital, UK. All women provided written 
informed consent and ethical approval was sought and granted by the North West (Liverpool 
East) Research Ethics Committee (REC Ref: 10/H1002/49) and by the Research and 
Development Director of Liverpool Women’s NHS Foundation Trust, Liverpool, United 
Kingdom. Indications for CS were previous CS (4, one of them presented breech), 
hypermobility (1), maternal hip operation (1), idiopathic intracranial hypertension (1), 
planned elective CS (1), and breech presentation (1). Biopsies were taken from the upper 
edge of the lower uterine segment incision immediately after delivery of the baby (Luckas & 
Wray, 2000). All biopsies were placed in Hanks balanced salt solution at 4°C and 
experiments were performed within 24 h of biopsy excision. The study conformed to the 
standards set by the Declaration of Helsinki, except for registration in a database. 
 
2.1.2 Plant Collection and Processing 
J. flava leaves were collected in Edo State, Nigeria, and identified at the Department of Plant 
Biology and Biotechnology, University of Benin, Nigeria, by Dr. H. A. Akinnibosun. A 
herbarium number of UBHj386 was provided for the plant. The leaves were cleaned, air-
dried for two weeks, and ground to powder. In order to prepare the methanol leaf extract of J. 
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flava (JF), the powdered leaves were macerated in methanol (500 g: 2 L) for 72 h. The 
mixture was continuously stirred during the period. After 72 h, the mixture was filtered, and 
the macerate was concentrated to a constant weight using a rotary evaporator set at 60°C 
(BUCHI Labortechnik AG, Flawil Switzerland). A yield of 20.14 w/w was obtained, and the 
constituted extract aliquot was stored at -80°C. 
 
2.1.3 Experimental Protocol 
Myometrial strips approximately 5 mm x 1 mm were isolated, such that the longitudinal axis 
of each strip was aligned with the direction of the muscle fibres (Arrowsmith et al., 2012). 
The uterine strips were mounted in a 1 mL chamber bath and secured with aluminium clips. 
The bath was continuously perfused with physiological saline of the following composition 
(in mM): 154 NaCl, 5.6 KCl, 1.2 MgSO4, 7.8 glucose, 10.9 HEPES, and 2.0 CaCl2, pH 7.4.  
The uterine strips were then placed under a resting tension of 2 mN. The rate of perfusion 
was set at 1.5 mL/min, and the temperature was maintained at 36°C.  A tension transducer 
(FT03, Grass Technologies, Slough, UK) attached to one end of the strip and connected to a 
data acquisition system (Axon) was used for recording contractility. Regular spontaneous 
contractions were achieved within 2 h. Strips that failed to develop spontaneous contractions 
within 2 h, even after challenging with high K
+
 (40 mM), were excluded.  
Once regular spontaneous contractions were achieved, cumulative concentrations of 
JF (0.0014 – 0.514 mg/mL) were added to the uterine tissue with each subsequent 
concentration added as soon as responses to preceding concentrations plateaued. At the end 
of the experiments, the tissues were washed, and recovery monitored for 1-2 h.  
All chemicals utilized were obtained from Sigma (Poole, Dorset, UK). 
 
2.2 Data Analysis 
The parameters of contraction (amplitude, frequency, duration, and area under the curve 
(AUC) were measured during a 20 min control period and in the last 20 min of each JF 
concentration using Origin Pro Software (Origin Lab, v8.1). Contractions in the last 20 min 
before cumulative additions of JF was taken as control and subsequent data expressed as a 
percentage of this control response. Measurement of duration included half maximal 
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amplitude, AUC calculations included increases in baseline where it occurred and was based 
on the mean of several contractions. The nonlinear regression sigmoidal dose response 
equation model was used to fit data from the amplitude, duration and AUC (GraphPad Prism 
Software, v. 5.01, California, USA). The sigmoidal dose response equation is represented by: 




Where X is log of concentration and Y is response. 
Data are presented as mean ± SD with one way ANOVA and Dunnett's post hoc test for 
multiple comparisons done with GraphPad Prism Software (v. 5.01, California, USA). 
P<0.05 was considered as minimum statistical significance and n = number of women.  
 
3.1 Results and Discussion 
Once contractions were established, the tissues contracted rhythmically for several hours 
(data not shown). JF inhibited spontaneous contractions of the human myometrium (Fig. 1). 
On analysis of contraction parameters, JF inhibited the amplitude of contraction (Fig. 2a) in a 
concentration-dependent manner, with significant inhibition obtained at 0.044, 0.114, 0.214 
and 0.514 mg/ml (P <0.01; 0.001; 0.001 respectively, n=9). As amplitude decreased, the 
frequency simultaneously increased until contractions were abolished (Fig. 1). JF did not 
significantly alter duration except at 0.514 mg/ml (by which time most tissues had ceased 
contracting; data not shown). JF inhibited total contractility (AUC) in a concentration-
dependent manner with significant inhibitions (P < 0.05) obtained at 0.114, 0.214 and 0.514 
mg/mL (n=9) (Fig. 2b). Some of the uterine tissues were monitored for 1-2 h after JF was 
removed and these showed up to ≈ 30-40% recovery (Supplementary Figure 1). To support 
this observation, our previous study in mice showed similar recovery (less than 50%) after 
cumulative additions of JF, and when single concentrations of JF were utilized (which will be 
the likely scenario when utilized clinically), almost total recovery was achieved (Bafor et al., 
2019). The IC50 of JF on the amplitude and area under the curve were calculated as 0.01 ± 
1.10 mg/ml and 0.13 ± 1.18 mg/ml respectively. The data utilized for plots and analysis in 
this study are presented as Supplementary Data.  
JF has been shown in this study to inhibit the isolated human myometrium as potently as it 
inhibited the mouse myometrium within very similar concentrations (Bafor et al., 2019). The 
inhibition pattern observed with the mouse uterus was also observed on the human 
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myometrium. JF inhibits the amplitude of contraction in a concentration-dependent manner 
with a corresponding increase in frequency, which was only reduced when contractions were 
completely abolished (Bafor et al., 2019). JF was also shown to inhibit Ca
2+
- entry through 
voltage-gated channels (VGCCs) and also inhibits intracellular Ca
2+
 release through inositol 
triphosphate (IP3) and ryanodine receptors (RyRs) in the non-pregnant mouse uterus (Bafor et 
al., 2019).  The mechanisms of JF in the mouse myometrium maybe similar to the human 
myometrium, although further studies will be required to confirm this. This is vital in the 
context of this study, as increases in Ca
2+
- within the myometrium drives myometrial 
contractility via myosin light chain kinase-dependent calcium-calmodulin pathway (Sanborn, 
2001). Nifedipine is an L-type Ca
2+
-channel blocker (Moynihan, Smith, & Morrison, 2008) 
that additionally acts through inhibition of outward K
+
 currents and inhibition of capacitative 
Ca
2+
 entry (Young et al., 2001), has shown clinical relevance in inhibiting uterine 
contractions in women with threatened PTL compared to atosiban (Al-Omari et al., 2008). 
However, use of nifedipine results in maternal complications (Al-Omari et al., 2006) such as 
severe hypotension and can also result in fetal death (van Veen et al., 2005). Thus JF which 
has shown similar calcium-blocking effects might prove safer and more efficacious in the 
management of uterine contractions arising from PTL. 
The increased frequency associated with JF may have resulted from the phytosterols 
contained in JF (Bafor et al., 2019). It appears that progesterone has the unique property of 
producing a simultaneous inverse occurrence with the amplitude and frequency of uterine 
contractions (Fanchin et al., 2000; Fanchin et al., 2001) and that this unique activity of 
increased frequency in the presence of decreasing amplitude is common with substances or 
plants with a dominance of phytosterols (Gwehenberger et al., 2004; Sukwan et al., 2014). 
The inverse activity may also be a property modulated by chloride conductance in the uterus, 
which is known to regulate uterine contraction frequency (Dodds et al., 2015) specifically.  
Interestingly, progesterone has been shown to attenuate the inhibitory effect of nifedipine on 
uterine contractility in vivo (Hajagos-Tóth et al., 2009). This is despite induction of rapid 
relaxation of the amplitude of myometrial contractions by progesterone (Anderson et al., 
2009). Though yet to be investigated, it can be speculated that the combined property of 
Ca
2+
-channel blockade and presence of phytosterols, may contribute to better efficacy of JF 
over nifedipine.  
 This is a pilot study that clearly shows the tocolytic potential of JF for human uterine 
contractility disorders. Previous safety studies on mice showed JF to be relatively safe, even 
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at high doses of 5 g/kg (Bafor et al., 2019). Our previous studies have also shown JF to have 
mild estrogenic activities at low doses (Bafor et al., 2020), which is beneficial to its continued 
use on humans. That JF reproducibly and effectively inhibited human myometrial 
contractility in this study, places JF as a lead plant in the drug discovery process for the 
development of tocolytic drugs. There are however some limitations to the study. With JF 
being a crude plant extract with several interacting compounds, we were unable to determine 
molecular weights and therefore molarities of specific compounds which would then have 
been compared with existing tocolytic drugs. Nonetheless, future studies on the plant should 
involve bioassay-guided fractionation, isolation and purification of active secondary 
metabolites from the plant involved in myometrial inhibition. Off-target effects of JF should 
also be studied. 
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Figure 1. Original representative recording showing the ex-vivo effect of JF (0.0014 – 0.514 
mg/mL) on spontaneous myometrial contractility. 
Figure 2. Effect of JF on ex-vivo parameters of contractility in the pregnant human 
myometrium. (a) JF inhibited the amplitude of spontaneous myometrial contractility; (d) JF 
also inhibited total contractility in the pregnant myometrium n = 9 women; **P<0.05; 
***P<0.0001; ****P<0.00001 compared to control. 
 
 
 
 
 
 
 
 
 
 
 
 
 


